Thermo Fisher Scientific Inc. (Thermo Fisher) and Beijing tricision Biotech Co., Ltd. (tricision) have signed a Memorandum of Understanding (MOU) for global commercial collaboration, building on their existing strategic partnership. Under the principles of "mutual benefit and shared development," the two companies will deepen their cooperation in biopharmaceutical research, quality control, and manufacturing.

The expanded partnership leverages tricision's capabilities across its Messenger RNA (mRNA) platform, Nanodelivery Platform (NP), regulatory filing and registration platform, drug discovery platform, proprietary patents, and the full-chain customized Contract Development and Manufacturing Organization (CDMO) services offered by its subsidiary, Yixing Chenggong New Drug Development Co., Ltd. (Chenggong New Drug). These assets will be combined with Thermo Fisher's solutions, global market reach, and customer networks in cell and gene therapy to drive deep, integrated collaboration.

Mr. Liu Dong, Chief Executive Officer (CEO) of tricision, stated: "tricision's commercial team will continue to work closely with Thermo Fisher, and we are very pleased to pursue global commercial collaboration." Thermo Fisher, in turn, will provide maximum support with its global market access, customer relationships, and product and process technologies to advance tricision's product development, Investigator-Initiated Trials (IITs), clinical trials, and commercial manufacturing in the cell therapy space.

The signing ceremony took place at the Thermo Fisher Customer Experience Center in Shanghai. Following the ceremony, Mr. Liu Dong and the tricision leadership team toured the Center's laboratories, gaining deeper insight into Thermo Fisher's innovative technology platforms and products across multiple fields.

This strategic partnership is expected to significantly accelerate the development of tricision's innovative cell therapies and help bring new hope to more patients.